Diabetes
Refine Search
Pharmaceutical
Non-governmental organizations in India have jointly issued a letter calling on the country’s government to expand the scope of price control by bringing other essential and life saving medicines under price regulation in order to protect patients from overcharging and to promote public health. 22 August 2014
Pharmaceutical
Acute pancreatitis involves the pancreas digesting itself resulting in severe abdominal pain, vomiting and systemic inflammation. Every year in the UK around 20,000 patients are diagnosed with the disease resulting in 10,000 deaths. 22 August 2014
Biosimilars
The US Food and Drug Administration yesterday granted tentative approval for Basaglar (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes. 19 August 2014
Pharmaceutical
Danish insulin giant Novo Nordisk has accepted a fine of 500,000 kroner ($89,735), imposed by the Public Prosecutor in a suit filed by the Danish Financial Supervisory Authority. 18 August 2014
Biotechnology
Endocrine specialists Biodel has seen positive preliminary results from a Phase IIa trial of its insulin formulation BIOD-531. 12 August 2014
Pharmaceutical
French pharma major Sanofi has entered into a worldwide exclusive licensing agreement with the USA’s MannKind Corp for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. 11 August 2014
Pharmaceutical
Positive new pivotal Phase III data about Xultophy (insulin degludec/liraglutide), formerly known as IDegLira, which is being developed by Danish diabetes care giant Novo Nordisk as a once-daily therapy for adults with type 2 diabetes, has just been published in Diabetes Care, demonstrating efficacy and tolerability of the drug combination. 11 August 2014
Biosimilars
Indian generic drugmaker Lupin has entered into a strategic distribution agreement with LG Life Sciences (South Korea) to launch insulin glargine, a novel insulin analogue under the brand name Basugine. 11 August 2014
Pharmaceutical
The US Food and Drug Administration has approved US health care giant Johnson & Johnson subsidiary Janssen Pharmaceuticals’ Invokamet, a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet, for the treatment of adults with type 2 diabetes. 9 August 2014
Pharmaceutical
In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether Danish diabetes care giant Novo Nordisk’s Tresiba (insulin degludec), alone or in combination with other blood-glucose lowering drugs, offers an added benefit over the appropriate comparator therapy. 8 August 2014
Pharmaceutical
With the recent approval of Jardiance (empagliflozin) in the USA, Eli Lilly and its partner, German family-owned pharma major Boehringer Ingelheim, have taken another step towards owning the most comprehensive diabetes portfolio in the industry, a new study suggests. 7 August 2014
Pharmaceutical
Danish diabetes care giant Novo Nordisk released first-half 2014 financial results this morning, showing that sales increased 7% in local currencies and 1% in Danish kroner to 41.97 billion kroner ($7.57 billion). 7 August 2014
Pharmaceutical
Pharmaceutical companies are racing to find a new form of obesity drug as patient numbers spiral and current products suffer from poor efficacy and reputation, according to new research from analyst firm Datamonitor Healthcare. 6 August 2014
Pharmaceutical
The US Food and Drug Administration on Friday approved Jardiance (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D). 2 August 2014
Pharmaceutical
US pharma major Eli Lilly has reached an agreement with one of Russia’s leading drugmakers, R-Pharm, for the production of its Humulin (insulin) in Russia. 29 July 2014
Pharmaceutical
The global insulin market was valued at $19.99 billion in 2012 and is expected to expand at a compound annual growth rate (CAGR) of 6.1% from 2013 to 2019 to reach $32.24 billion in 2019. 28 July 2014
Biosimilars
At its July 2014 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued positive opinions for the recommendation of a number of new drugs, including the following: 26 July 2014
Pharmaceutical
Australia’s Minister for Education, Christopher Pyne, and Minister for Health, Peter Dutton, have today announced the government’s approval of A$35 million ($32.8 million) to advance research in the critical area of diabetes. 10 July 2014
Pharmaceutical
Chinese drugmaker Yabao Pharmaceutical has entered a strategic partnership with US pharma major Eli Lilly to co-develop Lilly's leading glucokinase activator (GKA), LY2608204, which has completed Phase I studies in the USA in addition to extensive preclinical development for the treatment of diabetes. 8 July 2014
Biotechnology
The Scottish Medicines Consortium (SMC) has issued guidance on Anglo-Swedish drug major AstraZeneca’s Forxiga (dapagliflozin), a first-in-class sodium-glucose co-transporter 2 (SGLT2) inhibitor for type 2 diabetes. 8 July 2014
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze